Filing Analysis
Vaxart, Inc. entered into Modification No. 7 of its BARDA-funded Project Agreement with Advanced Technology International. The modification reflects a significant reduction in total available funding due to a partial termination ordered by BARDA.
🚩 Red Flags
- Significant reduction in total project funding (down ~$116M).
- Partial termination of the agreement by BARDA on August 5, 2025.
- Reduction in clinical trial scope/participant enrollment (approx. 50% decrease).
📋 Key Facts
- Total available funding under the modified agreement is approximately $345 million.
- The modification represents an approximate $116 million decrease from the previous modification amount.
- Funding reduction follows a ~50% reduction in trial participants due to a BARDA partial termination ordered on August 5, 2025.
- The funding includes approximately $68 million in firm fixed price amounts and remaining funds for cost reimbursement.
- Modification allows for the release of approximately $29 million specifically for trial completion and exploratory analyses.
Vaxart, Inc. has received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement. The company is currently non-compliant but has been granted until June 30, 2025, to meet the standard or face potential delisting.
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq minimum bid price requirement ($1.00 rule).
- Explicit mention of a potential reverse stock split to regain compliance.
- Ongoing non-compliance despite an initial 180-day grace period.
📋 Key Facts
- Nasdaq issued an Extension Letter on December 31, 2024.
- The company failed to regain compliance during the initial 180-day period ending December 30, 2024.
- A new compliance deadline has been set for June 30, 2025.
- Compliance requires a minimum closing bid price of $1.00 per share for at least 10 consecutive trading days.
- The company explicitly mentioned considering a reverse stock split as a method to cure the deficiency.
Vaxart, Inc. has entered into Modification No. 4 to its Project Agreement with Advanced Technology International (a BARDA-funded entity). This modification significantly increases both the total funding ceiling and the currently allotted funds for their Phase 2b COVID-19 vaccine candidate trial.
🚩 Red Flags
- The filing includes standard forward-looking statement warnings regarding 'continuing operating losses,' which is a common risk factor for micro-cap biotech firms awaiting clinical milestones.
📋 Key Facts
- Modification No. 4 entered into on December 20, 2024.
- Total estimated funding ceiling increased to approximately $460.7 million (an increase of ~$4.6 million).
- Total amount currently allotted and available for payment increased to approximately $134.2 million (an increase of ~$37.7 million).
- Funds are designated for a Phase 2b comparative study of the oral pill XBB COVID-19 vaccine candidate against an FDA-approved mRNA comparator.
- Additional funding covers acquisition/distribution of clinical materials and site readiness for efficacy and safety portions of the trial.
Vaxart, Inc. announced the completion of enrollment for the sentinel cohort of its Phase 2b clinical trial for an oral COVID-19 vaccine candidate. The cohort consists of 404 participants randomized between the company's vaccine and an approved mRNA comparator.
📋 Key Facts
- Completion of enrollment for the sentinel cohort of a Phase 2b clinical trial was announced on December 2, 2024.
- The sentinel cohort comprises 404 total participants.
- At least 200 participants received Vaxart's oral COVID-19 vaccine candidate; approximately 200 received an approved mRNA comparator.
- The final dose for enrollment was administered on November 26, 2024.
Vaxart, Inc. filed an 8-K to furnish its third quarter 2024 financial results and a business update via press release. The filing serves as a formal announcement of the company's quarterly performance for the period ended September 30, 2024.
📋 Key Facts
- Report date: November 13, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing includes a press release titled 'Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results' as Exhibit 99.1.
Vaxart, Inc. has terminated its Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. and B. Riley Securities, Inc., effective October 18, 2024.
🚩 Red Flags
- Termination of an ATM (At-the-Market) program can sometimes indicate a company is moving away from dilutive financing, but in micro-caps, it may also signal the end of a primary source of immediate liquidity/cash runway extension.
📋 Key Facts
- Termination of the Sales Agreement is effective October 18, 2024.
- The Company will not incur any termination penalties for ending the agreement.
- Since September 15, 2021, the company has sold 17,501,561 shares via this agreement.
- Aggregate gross proceeds from these sales totaled approximately $28.6 million.
- The Company stated it does not intend to issue or sell any additional shares under this specific agreement prior to termination.
Vaxart, Inc. entered into a modification to its BARDA-funded Project Agreement, significantly increasing both the total funding ceiling and the currently allotted funds for its Phase 2b clinical trial of an oral COVID-19 vaccine candidate.
🚩 Red Flags
- The filing includes forward-looking statement warnings regarding the company's continuing operating losses.
📋 Key Facts
- Entered into Modification No. 3 to the ATI-RRPV Project Award Agreement on September 27, 2024.
- Total estimated funding ceiling increased by ~$3.2 million to approximately $456.1 million.
- Currently allotted funding for the Trial increased by ~$30.8 million to approximately $96.5 million.
- Funding includes provisions for manufacturing a vaccine construct targeting the KP.2 strain.
- BARDA authorized the commencement of the 'sentinel portion' of the Phase 2b trial involving a cohort of 400 individuals comparing Vaxart's XBB vaccine against an mRNA comparator.
Vaxart, Inc. filed an 8-K to furnish its second quarter 2024 financial results and a business update via press release. The filing is a routine disclosure of quarterly earnings and operational progress.
📋 Key Facts
- Report date: August 8, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing includes Exhibit 99.1 containing the business update and financial results
- Information is furnished under Item 2.02 but not 'filed' for purposes of Section 18 liability
Vaxart, Inc. received a notice from Nasdaq stating it is non-compliant with the $1.00 minimum bid price requirement. The company has 180 days to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice from Nasdaq
- Failure to maintain minimum bid price requirement ($1.00)
- Potential necessity of a reverse stock split to regain compliance
📋 Key Facts
- Received written notice from Nasdaq on July 2, 2024.
- Non-compliance is due to failure to maintain a $1.00 minimum bid price for the 30 consecutive business days between May 17, 2024, and July 1, 2024.
- The company has an initial 180-day period to regain compliance, expiring December 30, 2024.
- Compliance can be achieved if the stock closes at $1.00 or higher for 10 consecutive business days.
- A second 180-day extension may be available if the company intends to effect a reverse stock split to cure the deficiency.
This is an amendment to a previous 8-K filing intended to correct a calculation error regarding the voting results of Proposal No. 2 from the 2024 Annual Meeting. The correction does not change the outcome of the vote, which was for the increase in authorized common stock.
🚩 Red Flags
- Calculation error in official voting results reported to the SEC (though outcome remains unchanged).
📋 Key Facts
- The filing is an amendment (8-K/A) to a report filed on June 13, 2024.
- Proposal No. 2 involved increasing authorized common stock from 250,000,000 to 350,000,000 shares.
- Corrected voting results for Proposal 2: 35,936,013 For; 21,134,398 Against; 491,543 Abstentions; 47,701,989 Broker Non-Votes.
- The correction was necessitated by a calculation error identified in the results provided by an outside voting tabulation firm.
Vaxart, Inc. filed an 8-K to furnish a press release containing a business update issued on June 17, 2024. The filing is made under Item 7.01 (Regulation FD Disclosure) and does not contain material financial changes or structural shifts in this specific document.
📋 Key Facts
- The company issued a press release providing a business update on June 17, 2024.
- The filing is categorized under Item 7.01 (Regulation FD Disclosure).
- The information provided is furnished but not 'filed' for purposes of Section 18 liability.
Vaxart, Inc. entered into an underwriting agreement with Oppenheimer & Co. Inc. to conduct a registered direct offering of 50,000,000 shares at $0.80 per share. The offering aims to raise approximately $40 million in gross proceeds.
🚩 Red Flags
- Significant dilution: Issuance of 50 million new shares will significantly dilute existing shareholders.
- Low share price: The $0.80 pricing is characteristic of micro-cap companies facing liquidity needs or struggling to maintain higher valuations.
📋 Key Facts
- Offering size: 50,000,000 shares of common stock.
- Price per share: $0.80.
- Expected gross proceeds: $40,000,000 (before discounts and expenses).
- Underwriter: Oppenheimer & Co. Inc.
- Closing date expected: June 17, 2024.
- Offering type: Registered direct offering pursuant to an existing S-3 registration statement.
Vaxart, Inc. entered into a Project Agreement with Advanced Technology International (funded by BARDA) to conduct a Phase 2b comparative study of its oral XBB COVID-19 vaccine candidate against an FDA-approved mRNA vaccine. The agreement provides for potential total funding of up to $453 million.
🚩 Red Flags
- Funding is contingent upon BARDA's decision to continue funding after the initial phase.
- Clinical trial success is not guaranteed; results depend on achieving primary endpoints regarding relative efficacy and safety.
📋 Key Facts
- Entered into Project Agreement with Advanced Technology International (BARDA-funded) on June 13, 2024.
- Total potential funding: Up to approximately $453 million.
- Initial award amount: Up to ~$65.7 million ($64.7M fixed fee + cost reimbursement).
- Phase 2b study design: Double-blind, multi-center, randomized, comparator-controlled trial involving ~10,000 healthy adults.
- Trial objective: Evaluate relative efficacy, safety, and immunogenicity of oral XBB vaccine vs. approved mRNA injectable.
- Study enrollment details: 5,000 participants receiving Vaxart candidate; 5,000 receiving mRNA comparator.
Vaxart, Inc. reported the results of its 2024 annual meeting of stockholders held on June 11, 2024. Shareholders approved several key measures including an increase in authorized shares and amendments to equity incentive plans.
🚩 Red Flags
- Significant increase in authorized shares (100 million additional shares) can lead to future dilution if used for capital raises.
📋 Key Facts
- Stockholders increased authorized common stock from 250,000,000 to 350,000,000 shares (Proposal 2).
- The 2019 Equity Incentive Plan was amended to increase reserved shares by 15,000,000 to a total of 43,900,000 (Proposal 3).
- The 2022 Employee Stock Purchase Plan was amended to increase reserved shares by 1,800,000 to a total of 3,600,000 (Proposal 4).
- WithumSmith+Brown, PC was ratified as the independent registered public accounting firm for FY2024 (Proposal 5).
- All six proposals presented at the annual meeting were approved by stockholders.
Vaxart, Inc. filed an 8-K to furnish its first quarter 2024 financial results and a business update via press release. The filing is primarily for compliance regarding the disclosure of quarterly earnings.
📋 Key Facts
- Report date: May 13, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing includes a press release titled 'Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results' as Exhibit 99.1.
- Information is furnished under Item 2.02 but not considered 'filed' for purposes of Section 18 liability.
Vaxart, Inc. announced the completion of topline analysis for its Phase 1 clinical trial regarding an oral pill bivalent norovirus vaccine candidate.
📋 Key Facts
- Completed topline analysis for Phase 1 clinical trial on April 30, 2024.
- The trial evaluated an oral pill bivalent norovirus vaccine candidate.
- Results were communicated via a press release issued on the same date.
Vaxart, Inc. filed an 8-K to announce its full year 2023 financial results and provide a business update via press release.
📋 Key Facts
- Report date: March 14, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes Exhibit 99.1 containing the business update and financial results.
- Signed by Michael J. Finney, Ph.D., Interim CEO and Chair of the Board.
Vaxart, Inc. has appointed Steven Lo as the new Chief Executive Officer, President, and principal executive officer, effective March 18, 2024. Dr. Michael J. Finney will transition from his interim CEO role to serve as Chair of the Board.
🚩 Red Flags
- Leadership transition in a micro-cap biotech can often signal shifts in strategic direction or internal restructuring.
📋 Key Facts
- Steven Lo appointed as CEO, President, and principal executive officer effective March 18, 2024.
- Dr. Michael J. Finney steps down as Interim CEO but remains as Chair of the Board.
- Mr. Lo's compensation includes a $600,000 annual base salary and a target bonus of up to 50% of base salary.
- Equity incentives for Mr. Lo include an option for 1,000,000 shares (48-month vesting) and 250,000 RSUs (vesting over 4 years).
- Mr. Lo brings significant biotech experience from Valitor, Inc., Zosano Pharma, Puma Biotechnology, and Genentech.
Vaxart, Inc. adopted the 2024 Inducement Award Plan to facilitate the hiring of new employees and re-hiring of former staff through equity awards. The plan reserves 3,000,000 shares of common stock for issuance under this program.
🚩 Red Flags
- Potential dilution of existing shareholders via the reservation of 3,000,000 new shares.
📋 Key Facts
- Board adopted the Vaxart, Inc. 2024 Inducement Award Plan on February 27, 2024.
- The plan was adopted without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4).
- Reserved 3,000,000 shares of common stock for issuance under the new plan.
- Awards are limited to new hires or employees being rehired after a bona fide interruption in employment.
- The plan includes restricted stock units (RSUs) and other stock-based awards; however, incentive stock options may not be issued under this specific 2024 plan.
Vaxart, Inc. announced that it has regained compliance with Nasdaq's minimum bid price requirement. This follows a period of non-compliance where the stock was at risk of delisting.
🚩 Red Flags
- Historical delisting risk (though currently resolved)
📋 Key Facts
- The Company received a letter from Nasdaq Listing Qualifications Staff on February 14, 2024.
- Compliance regained for Nasdaq Listing Rule 5550(a)(2) regarding minimum bid price requirements.
- Compliance was achieved because the common stock closed at $1.00 or more per share for ten consecutive business days.
Vaxart, Inc. filed an amendment to its previous 8-K to disclose the finalized separation agreement for former President and CEO Andrei Floroiu. The agreement includes various severance benefits in exchange for a release of claims and restrictive covenants.
🚩 Red Flags
- CEO departure often signals internal transition or strategic shifts in micro-cap biotech firms.
- Significant cash outflow required for severance benefits (salary + health insurance + bonus).
📋 Key Facts
- Andrei Floroiu resigned as President, CEO, and Board Member (effective date of original report: Jan 15, 2024).
- Separation Agreement finalized on January 31, 2024.
- Severance includes 12 months of continued base salary and subsidized health insurance premiums.
- Includes potential 2023 bonus payout if applicable.
- Accelerated vesting of equity awards through September 30, 2024.
- Two-year window provided to exercise vested stock options.
- Agreement includes non-competition, non-solicitation, and non-disparagement covenants.
Vaxart, Inc. has received a second 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement. The company must maintain a closing bid price of at least $1.00 for 10 consecutive trading days by July 15, 2024, or face potential delisting.
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq minimum bid price requirement.
- Potential for a reverse stock split to artificially inflate share price.
- Ongoing failure to maintain minimum listing standards despite previous extension.
📋 Key Facts
- Nasdaq granted an extension until July 15, 2024, to cure the Bid Price Requirement deficiency.
- The company failed to regain compliance during the initial 180-day period (which expired January 17, 2024).
- Compliance requires a minimum closing bid price of $1.00 for at least 10 consecutive trading days.
- The company has indicated it is considering a reverse stock split as a potential method to regain compliance.
- Vaxart received an award from the U.S. Department of Health and Human Services on January 19, 2024, to fund clinical study preparation.
Vaxart, Inc. entered into a securities purchase agreement with RA Capital Healthcare Fund, L.P. to raise approximately $10 million through the issuance of common stock.
🚩 Red Flags
- Significant dilution for existing shareholders due to the issuance of over 15 million new shares.
- The offering price of $0.65 per share is relatively low, which may indicate a need for immediate liquidity in a micro-cap environment.
📋 Key Facts
- The Company will issue 15,384,615 shares of common stock to RA Capital Healthcare Fund, L.P.
- The offering price is set at $0.65 per share.
- Total transaction value is approximately $10 million.
- The offering is being conducted under a previously declared effective shelf registration statement (Form S-3) from May 5, 2023.
- Closing is expected on or about January 18, 2024.
Vaxart, Inc. announced the resignation of its President and CEO, Andrei Floroiu, effective January 15, 2024, alongside the appointment of Board Chair Dr. Michael J. Finney as Interim CEO. Simultaneously, the company secured a significant $9.27 million contract from the U.S. Department of Health and Human Services (ASPR) to support clinical trial planning for its XBB vaccine candidate.
🚩 Red Flags
- Sudden departure of the President and Chief Executive Officer (Officer Departure).
- Multiple material events in a single filing (Material Agreement + Officer Departure) increases volatility risk.
- The company mentions 'continuing operating losses' in its forward-looking statements disclaimer.
📋 Key Facts
- CEO Andrei Floroiu resigned as President, CEO, and Board Member on January 15, 2024.
- Dr. Michael J. Finney appointed Interim CEO effective January 16, 2024; he will receive a base salary of $595,000/year plus a 50% target bonus.
- Awarded an ASPR Contract (75A50124C00002) valued at $9,271,193.00 for Phase 2b clinical trial planning of the XBB vaccine candidate.
- David Wheadon, M.D. appointed as Lead Director with a $25,000 annual cash retainer.
- The company is conducting a search for a permanent CEO successor.